RiboMed and NuvOx Pharma to Collaborate on Brain Cancer Drug and Companion Diagnostic Test

 

 

RiboMed Biotechnologies, Inc. and NuvOx Pharma today jointly announced that they have entered into a collaborative agreement that will utilize RiboMed’s epigenetic biomarker test, GliomaSTRAT™, to characterize tumors from brain cancer patients and correlate response to NuvOx’s new drug, NVX-108 in the treatment of Glioblastoma multiforme (GBM).Continue reading

Sign Up for the Alzheimer’s Prevention Registry

alzheimers prevention registry


Launching a research study often takes years of work, and most of the effort occurs behind the scenes. The exciting news is that several of these studies have just launched or are close to being ready to start recruiting participants through the Alzheimer’s Prevention Registry. And more studies will launch in the coming years. Here is a snapshot of a few of the studies that will be taking place in the United States and other countries around the world:

  • A trial in 1000 adults ages 65-85 who have evidence of amyloid plaque build up in their brain based on a screening PET scan, and  who are at risk for Alzheimer’s disease but are still cognitively healthy to determine whether an experimental medication may delay cognitive decline
  • A trial in nearly 6,000 adults ages 65-83 to learn about the genetic risk for developing mild cognitive impairment due to Alzheimer’s disease and whether an experimental medication might delay the symptoms
  • Two trials in a rare, hereditary form of early-onset Alzheimer’s with experimental medications to determine if treatment delays cognitive impairment
  • And many more.

Imagine having tens of thousands of volunteers awaiting an e-mail from the Registry announcing that a study is ready to begin enrollment in their communities.  Researchers could quickly screen and fill their enrollment sites in a matter of weeks or months, not years. Saving this precious time means we get to answers faster.
This is why the Alzheimer’s Prevention Registry will play a vital role in these and other prevention trials.

Take action:   While researchers work to get these and other studies ready, you can help by continuing to encourage your friends and family to sign up for the Registry.

 

 

The Economist recognises Genentech for corporate innovation

Genentech was named the winner of the Corporate Award for its consistent and impressive record in breakthrough research and innovation at The Economist’s Innovation Awards on  Monday November 25th, 2013.

Genentech Web

The Corporate award celebrates Genentech’s track record in research and innovation. Genentech was founded by biochemist Herbert Boyer and venture capitalist Robert Swanson in 1976. It has been a wholly owned subsidiary of the Roche Group since 2009. Widely considered the founder of the biotech industry, the company changed the face of medicine when it became the first to scale up protein-manufacturing from the small quantities used for research to the much larger quantities needed to treat patients. The firm’s achievements include the development of the first recombinant DNA medicine ever marketed, the first targeted medicine approved to treat cancer and the first medicine shown to improve vision in the most common cause of blindness in adults.
Genentech’s research scientists have earned more than 10,500 patents and brought breakthrough medicines to people with serious diseases such as cystic fibrosis, cancer, rheumatoid arthritis and stroke. Overall, it has 35 medicines on the market and at least 30 more in clinical development. In 2012, sales of Genentech’s medicines in the United States were CHF13.856 billion.